RT Book, Section
A1 Clark, Jeffrey W.
A2 Chabner, Bruce A.
A2 Longo, Dan L.
SR Print(0)
ID 1127648839
T1 Pancreatic Cancer
T2 Harrison's Manual of Oncology, 2e
YR 2016
FD 2016
PB McGraw-Hill Education
PP New York, NY
SN 9780071793254
LK hemonc.mhmedical.com/content.aspx?aid=1127648839
RD 2024/04/24
AB For  most  patients,  pancreatic  adenocarcinoma  remains  highly  lethal  and  is  the  fourth  leading  cause  of  deaths  from  cancer  in  the  USA.  Less  than  5%  survive  5  years  after  diagnosis.  Surgical  resection  is  the  only  curative  treatment.  However,  the  cure  rate  with  surgery  is  only  18%–25%  and  most  patients  are  not  surgical  candidates.  Patients  with  unresectable  disease  can  have  symptoms  palliated  by  chemotherapy  and/or  radiation  therapy.  However,  these  have  not  significantly  impacted  5-year  survival.  Improved  understanding  of  pancreatic  cancer  biology  continues  to  provide  new  therapeutic  ideas.  Trials  are  evaluating  whether  new  approaches  to  earlier  diagnosis  or  improvements  in  radiation  therapy,  chemotherapy  (including  targeted  therapy),  and/or  immunotherapy  (e.g.,  vaccines,  therapy  aimed  at  inhibiting  negative  immunoregulatory  proteins)  can  impact  survival.